- Home
- NRIX vs INVA Comparison
NRIX vs INVA Comparison
Compare NRIX & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- INVA
- Stock Information
- Founded
- NRIX 2009
- INVA 1996
- Country
- NRIX United States
- INVA United States
- Employees
- NRIX N/A
- INVA N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- NRIX Health Care
- INVA Health Care
- Exchange
- NRIX Nasdaq
- INVA Nasdaq
- Market Cap
- NRIX 1.4B
- INVA 1.2B
- IPO Year
- NRIX 2020
- INVA 2004
- Fundamental
- Price
- NRIX $19.60
- INVA $18.75
- Analyst Decision
- NRIX Strong Buy
- INVA Buy
- Analyst Count
- NRIX 17
- INVA 1
- Target Price
- NRIX $30.29
- INVA N/A
- AVG Volume (30 Days)
- NRIX 771.6K
- INVA 684.8K
- Earning Date
- NRIX 02-13-2025
- INVA 02-27-2025
- Dividend Yield
- NRIX N/A
- INVA N/A
- EPS Growth
- NRIX N/A
- INVA 46.55
- EPS
- NRIX N/A
- INVA 0.99
- Revenue
- NRIX $56,424,000.00
- INVA $352,745,000.00
- Revenue This Year
- NRIX N/A
- INVA $16.20
- Revenue Next Year
- NRIX $3.79
- INVA N/A
- P/E Ratio
- NRIX N/A
- INVA $18.93
- Revenue Growth
- NRIX N/A
- INVA 21.46
- 52 Week Low
- NRIX $7.65
- INVA $14.33
- 52 Week High
- NRIX $29.56
- INVA $21.28
- Technical
- Relative Strength Index (RSI)
- NRIX 48.04
- INVA 66.59
- Support Level
- NRIX $18.75
- INVA $17.01
- Resistance Level
- NRIX $20.50
- INVA $17.53
- Average True Range (ATR)
- NRIX 1.08
- INVA 0.28
- MACD
- NRIX 0.18
- INVA 0.21
- Stochastic Oscillator
- NRIX 70.00
- INVA 93.05
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.